Clinical trial
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and…
NCT00329589 · Sidney Kimmel Cancer Center at Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00329589 |
|---|---|
| Title | A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients |
| Official title | A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients |
| Lead sponsor | Sidney Kimmel Cancer Center at Thomas Jefferson University, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain Cancer, Head and Neck Cancer, Cervix Cancer, Central Nervous System Neoplasms |
| Intervention type | Drug |
| Interventions | Velcade (bortezomib) |
| Enrollment | 54 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | May 25, 2006 |
| Last update posted | May 2, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: